Cingulate (CING) Registration filing summary

Company overview and business model

• Incorporated in Delaware with principal executive offices in Kansas City, KS.

• Operates under the primary SIC code 2834, indicating a focus in the pharmaceutical or biotechnology sector.

Management team and governance

• Shane J. Schaffer serves as Chief Executive Officer and Chairman.

• Jennifer L. Callahan is Chief Financial Officer and Principal Accounting Officer.

• Board includes directors Peter J. Werth, Bryan Lawrence, Jeffrey Ervin, John Roberts, and Jeff Hargroves.

• Officers and directors have granted power of attorney for filing amendments.

Offering details and pricing

• Registration statement filed on Form S-3 for a shelf offering, allowing securities to be sold from time to time after effectiveness.

• Securities may be offered on a delayed or continuous basis under Rule 415.

• Filing includes forms for common stock, preferred stock, warrants, debt securities, units, and subscription agreements.